Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results
March 15 2018 - 7:00AM
Neos Therapeutics, Inc.
(Nasdaq:NEOS), a
pharmaceutical company focused on developing, manufacturing and
commercializing innovative extended-release (XR) products using its
proprietary modified-release drug delivery technologies, today
reported financial results for the fourth quarter and full year
ended December 31, 2017 and provided a business update.
“We’ve launched three ADHD products in the last
two years and are very pleased with our product portfolio, which we
believe reflects both the strength of our unique technology
platform as well as our ability to develop, manufacture and
commercialize products,” said Vipin K. Garg, Ph.D., President and
CEO of Neos Therapeutics. “Our second product, Cotempla XR-ODT™, is
new to the market but already seeing strong adoption. We believe
this is, in part, the result of our established relationships with
nearly 11,000 healthcare professionals, their awareness of our
XR-ODT technology and their interest in using our innovative
products. With three synergistic Attention
Deficit/Hyperactivity Disorder (ADHD) products on the
market, we expect to see continued commercial growth and a
significant improvement in gross profit.”
Neos’ three commercial products are Adzenys
XR-ODT®, Cotempla XR-ODT™ and Adzenys
ER™ which launched in May 2016, October 2017 and
February 2018, respectively.
Commercial Product Highlights as
Reported by IQVIA (formerly called IMS Health)
|
Cumulative total EUTRx* (4Q17) |
Cumulative total EUTRx (4Q16) |
Year-over-year increase |
Cumulative total EUTRx since launch(as of
3.2.18) |
Patients switching from another medication
(as of 2.23.18) |
Adzenys XR-ODT® |
62,737 |
20,330 |
208.6% |
260,767 |
71% |
Cotempla XR-ODT™ |
12,073 |
N/A |
N/A |
37,168 |
79% |
TOTAL |
74,810 |
20,330 |
268.0% |
297,935 |
N/A |
*EUTRx = Equivalent Unit TRx
Additional Commercial Product Highlights
as Reported by IQVIA
- Continued Strong Growth in Adzenys XR-ODT and Cotempla
XR-ODT Prescription Trends: The cumulative total number of
EUTRx for Adzenys XR-ODT were 62,737 for the three months ended
December 31, 2017, an increase of 23.7% over the 50,697 for the
three months ended September 30, 2017. For Cotempla XR-ODT, the
cumulative total number of EUTRx for the three months ended
December 31, 2017 were 12,073, compared to 648 EUTRx for the three
months ended September 30, 2017.
- Market Share of Neos’ XR-ODT Products is
Increasing: The combined total weekly prescriptions for
Adzenys XR-ODT and Cotempla XR-ODT continued to grow and had
increased to 9,031 weekly EUTRx for the week ended March 2, 2018.
This represents an aggregate market share of 0.54% of the entire
ADHD market.
- The Number of Prescribers of Adzenys XR-ODT and
Cotempla XR-ODT Continues to Grow: As of December 31,
2017, 10,870 health care providers had written prescriptions for
Adzenys XR-ODT since its launch, and 1,949 health care providers
had written prescriptions for Cotempla XR-ODT
since its launch. As of the week ended February 16, 2018, those
numbers had increased to 11,619 and 3,480, respectively.
- Patient Switching from Another ADHD Medication
Continues to be an Important Driver of Product Uptake:
Doctors are switching patients over from other ADHD medications to
both Adzenys XR-ODT (71% switching) and Cotempla XR-ODT (79%
switching).
Recent Announcements
- In January 2018, the Company announced that study findings for
two of its ADHD medications, Cotempla XR-ODT and Adzenys ER, were
presented in three posters at the 2018 Annual Meeting of the
American Professional Society of ADHD and Related Disorders. The
results showed efficacy, safety and tolerability of Cotempla XR-ODT
in children 6-12 years of age in a laboratory classroom study, and
demonstrated bioequivalence of Adzenys ER with Adderall XR.
- On February 26, 2018, the Company announced the U.S. commercial
launch of Adzenys ER (amphetamine) Extended-Release Oral
Suspension, its third ADHD product. This product received approval
from the U.S. Food and Drug Administration (FDA) on September 15,
2017 for the treatment of ADHD in patients six years and older.
This extended-release liquid medication does not require
refrigeration or reconstitution at the pharmacy level. Adzenys ER
oral suspension utilizes the same proprietary modified-release drug
delivery technology as Adzenys XR-ODT.
Select Financial Results for the Fourth
Quarter and Fiscal Year Ended December 31, 2017
- Total product revenues were $7.8 million for the three months
ended December 31, 2017, compared to $3.5 million for the same
period in 2016, and for the fiscal year ended December 31, 2017,
total product revenues were $25.0 million, compared with $9.2
million for the same period in 2016. For the three months ended
December 31, 2017, total product revenues associated with dispensed
patient prescriptions for the Company’s ADHD products were $7.2
million.
Net product sales (in $millions) |
|
Q4 2017 |
Q4 2016 |
Change % |
FY 2017 |
FY 2016 |
Change % |
Adzenys XR-ODT |
$6.3 |
$2.2 |
186.4% |
$19.0 |
$3.0 |
533.3% |
Cotempla XR-ODT |
$0.9 |
N/A |
N/A |
$0.9 |
N/A |
N/A |
Generic Tussionex |
$0.6 |
$1.3 |
-53.8% |
$5.1 |
$6.2 |
-17.7% |
Total |
$7.8 |
$3.5 |
122.9% |
$25.0 |
$9.2 |
171.7% |
- The Company reported a gross profit of $5.0 million for the
three months ended December 31, 2017, compared to a gross loss of
$0.5 million for the same period in 2016, and for the fiscal
year ended December 31, 2017, gross profit was $12.6 million as
compared to a gross loss of $2.3 million for the same period of
2016.
- Research and development expenses for the three months ended
December 31, 2017, were $1.8 million, compared to $3.6 million for
the same period in 2016, and for the fiscal year ended December 31,
2017, research and development expenses were $9.0 million compared
to $12.2 million for the same period of 2016. The decrease in the
fourth quarter was primarily due to a decline in testing, materials
and supply expenses due to the approval of the Company’s ADHD
product candidates in 2017 coupled with a non-recurring FDA fee
associated with the filing of the New Drug Application for Adzenys
ER in 2016.
- Selling and marketing expenses were $11.9 million for the
three months ended December 31, 2017, compared to $9.7 million
for the same period in 2016, and for the fiscal year ended December
31, 2017, selling and marketing expenses were $46.9 million
compared to $49.3 million for the same period in 2016. The fourth
quarter increase was principally due to higher medical marketing
costs as well as increased transaction fees associated with the
higher level of prescriptions processed for the Company’s
products.
- General and administrative expenses for the three months ended
December 31, 2017, were $3.0 million compared to $3.0 million
for the same period in 2016, and for the fiscal year ended December
31, 2017, general and administrative expenses were $13.8 million
compared to $12.6 million for the same period in 2016.
- The Company reported a net loss of $14.2 million, or $0.49 per
share, for the three months ended December 31, 2017, compared to a
net loss of $18.4 million, or $1.14 per share, for the same
period in 2016. For the fiscal year ended December 31, 2017,
the Company reported a net loss of $66.2 million, or $2.68 per
share, compared to a net loss of $83.3 million, or $5.19 per share
for the fiscal year ended December 31, 2016.
- At December 31, 2017, the Company held $50.4 million in cash
and cash equivalents and short-term investments.
Conference Call Details Neos
management will host a conference call and live audio webcast to
discuss results and provide a company update at 8:30 a.m. ET today.
The live call may be accessed by dialing (877) 388-8985 for
domestic calls, or +1 (562) 912-2654 for international callers, and
referencing conference ID number 5653457. A live audio
webcast for the conference call will be available on the Investor
Relations page of the Company’s website at
http://investors.neostx.com/.
About Neos TherapeuticsNeos
Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company
focused on developing, manufacturing and commercializing products
utilizing its proprietary modified-release drug delivery technology
platforms. Adzenys XR-ODT® (amphetamine) extended-release orally
disintegrating tablets (see Full Prescribing Information, including
Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release
orally disintegrating tablets (see Full Prescribing Information,
including Boxed WARNING), and Adzenys-ER™ (amphetamine)
extended-release oral suspension (see Full Prescribing Information,
including Boxed WARNING), all for the treatment of ADHD, are the
first three approved products using the Company’s
extended-release technology platform. In addition, Neos
manufactures and markets its generic version of the branded product
Tussionex®1, an extended-release oral suspension of hydrocodone and
chlorpheniramine for the relief of cough and upper respiratory
symptoms of a cold (see Full Prescribing Information, including
Boxed WARNING). Additional information about Neos is available at
www.neostx.com.
1Tussionex® is a registered trademark of
the UCB Group of Companies.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of
1995, including statements concerning the commercialization of
Adzenys XR-ODT, Cotempla XR-ODT™ and Adzenys ER, our marketing
plans, and the therapeutic potential of our products.
Forward-looking statements generally relate to future events or our
future financial or operating performance. In some cases, you can
identify forward-looking statements because they contain words such
as “may,” “will,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential” or “continue” or
the negative of these words or other similar terms or expressions
that concern our expectations, strategy, plans or intentions. These
forward-looking statements reflect our current views about our
expectations, strategy, plans, prospects or intentions, which are
based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected in
or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control including, without
limitation, our ability to market and sell our products and other
risks set forth under the caption “Risk Factors” in our most
recently filed Annual Report on Form 10-K as updated by our
subsequently filed other SEC filings, including our
Quarterly Report(s) on Form 10-Q. We assume no obligation
to update any forward-looking statements contained in this document
as a result of new information, future events or otherwise.
|
|
Neos Therapeutics, Inc. and
Subsidiaries |
CONSOLIDATED BALANCE SHEETS |
(In thousands, except share and per share data) |
|
|
|
December 31, |
|
2017 |
|
2016 |
ASSETSCurrent Assets: |
|
|
Cash and
cash equivalents |
$ |
31,969 |
|
|
$ |
24,352 |
|
Short‑term investments |
|
18,448 |
|
|
|
15,430 |
|
Accounts
receivable, net of allowances for chargebacks and cash discounts of
$1,154 and $950, respectively |
|
13,671 |
|
|
|
6,135 |
|
Inventories |
|
13,459 |
|
|
|
5,767 |
|
Deferred
contract sales organization fees |
|
— |
|
|
|
720 |
|
Other
current assets |
|
5,093 |
|
|
|
2,865 |
|
Total current assets |
|
82,640 |
|
|
|
55,269 |
|
|
|
|
|
|
|
|
|
Property and equipment,
net |
|
8,203 |
|
|
|
7,076 |
|
Intangible assets,
net |
|
16,348 |
|
|
|
17,647 |
|
Other assets |
|
162 |
|
|
|
150 |
|
|
|
|
|
|
|
|
|
Total assets |
$ |
107,353 |
|
|
$ |
80,142 |
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
|
Current
Liabilities: |
|
|
Accounts
payable |
$ |
11,460 |
|
|
$ |
7,798 |
|
Accrued
expenses |
|
10,570 |
|
|
|
5,264 |
|
Deferred
revenue |
|
14,676 |
|
|
|
3,662 |
|
Current
portion of long‑term debt |
|
896 |
|
|
|
4,921 |
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
37,602 |
|
|
|
21,645 |
|
|
|
|
|
|
|
Long‑Term
Liabilities: |
|
|
Long‑term
debt, net of current portion |
|
58,938 |
|
|
|
58,599 |
|
Derivative liability |
|
1,660 |
|
|
|
— |
|
Deferred
rent |
|
1,083 |
|
|
|
1,174 |
|
Other
long-term liabilities |
|
180 |
|
|
|
272 |
|
|
|
|
|
|
|
|
|
Total long‑term liabilities |
|
61,861 |
|
|
|
60,045 |
|
|
|
|
|
|
|
Stockholders’ Equity
(Deficit): |
|
|
Preferred stock, $0.001
par value, 5,000,000 shares authorized, no shares issued or
outstanding at December 31, 2017 and December 31,
2016 |
|
— |
|
|
|
— |
|
Common stock, $0.001
par value, 100,000,000 authorized at December 31, 2017 and
December 31, 2016; 29,030,757 and 28,996,956 issued and
outstanding, respectively, at December 31, 2017;
16,079,902 and 16,060,996 issued and outstanding,
respectively, at December 31, 2016 |
|
29 |
|
|
|
16 |
|
Treasury stock, at
cost, 33,801 shares at December 31, 2017 and 18,906 shares at
December 31, 2016 |
|
(352 |
) |
|
|
(232 |
) |
Additional paid‑in capital |
|
274,584 |
|
|
|
198,787 |
|
Accumulated deficit |
|
(266,365 |
) |
|
|
(200,118 |
) |
Accumulated other comprehensive loss |
|
(6 |
) |
|
|
(1 |
) |
|
|
|
|
|
|
|
|
Total stockholders’ equity (deficit) |
|
7,890 |
|
|
|
(1,548 |
) |
Total
liabilities and stockholders’ equity (deficit) |
$ |
107,353 |
|
|
$ |
80,142 |
|
|
|
|
|
|
|
|
|
|
Neos Therapeutics, Inc. and
Subsidiaries |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(In thousands, except share and per share data) |
|
|
|
|
|
|
|
|
|
|
Three Months Ended December
31, |
|
|
Year Ended December
31, |
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
Net
product sales |
|
$ |
7,787 |
|
|
$ |
3,503 |
|
|
$ |
25,018 |
|
|
$ |
9,154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold |
|
2,778 |
|
|
4,020 |
|
|
12,391 |
|
|
11,437 |
|
Gross profit (loss) |
|
5,009 |
|
|
(517 |
) |
|
12,627 |
|
|
(2,283 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development expenses |
|
1,784 |
|
|
3,602 |
|
|
8,957 |
|
|
12,207 |
|
Selling and marketing
expenses |
|
11,851 |
|
|
9,661 |
|
|
46,881 |
|
|
49,291 |
|
General and
administrative expenses |
|
3,039 |
|
|
3,025 |
|
|
13,805 |
|
|
12,625 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
(11,665 |
) |
|
(16,805 |
) |
|
(57,016 |
) |
|
(76,406 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
(2,836 |
) |
|
(2,191 |
) |
|
(10,085 |
) |
|
(6,937 |
) |
Loss on debt
extinguishment |
|
— |
|
|
— |
|
|
— |
|
|
(1,187 |
) |
Other income, net |
|
276 |
|
|
622 |
|
|
854 |
|
|
1,197 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(14,225 |
) |
|
$ |
(18,374 |
) |
|
$ |
(66,247 |
) |
|
$ |
(83,333 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common
shares outstanding used to compute net loss per share, basic
and diluted |
|
28,746,608 |
|
|
16,062,685 |
|
|
24,751,091 |
|
|
16,052,390 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per
share of common stock, basic and diluted |
|
$ |
(0.49 |
) |
|
$ |
(1.14 |
) |
|
$ |
(2.68 |
) |
|
$ |
(5.19 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contacts:
Richard EisenstadtChief Financial OfficerNeos
Therapeutics(972) 408-1389reisenstadt@neostx.com
Sarah McCabeStern Investor Relations, Inc.(212)
362-1200sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024